Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections

Description

Due to rising antibiotic resistance, there has been a focus on non-antibiotic prophylactic measures for postmenopausal patients with recurrent urinary tract infections (rUTI), one of which is the safe and efficacious option of vaginal estrogen therapy. Standard application of vaginal estrogen cream entails intravaginal application of the cream twice a week, but some providers counsel patients with rUTI to apply a small, pea-sized amount to the periurethral area. This ideally reduces the amount of vaginal estrogen used while attaining a similar effect. However, to date, there is no data to prove that the periurethral technique of application is similar or non-inferior to intravaginal application in preventing UTI.

Conditions

Recurrent Urinary Tract Infection

Talk to us

Study Overview

On this page

Study Details

Study overview

Due to rising antibiotic resistance, there has been a focus on non-antibiotic prophylactic measures for postmenopausal patients with recurrent urinary tract infections (rUTI), one of which is the safe and efficacious option of vaginal estrogen therapy. Standard application of vaginal estrogen cream entails intravaginal application of the cream twice a week, but some providers counsel patients with rUTI to apply a small, pea-sized amount to the periurethral area. This ideally reduces the amount of vaginal estrogen used while attaining a similar effect. However, to date, there is no data to prove that the periurethral technique of application is similar or non-inferior to intravaginal application in preventing UTI.

Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections: TAPER (Techniques of APplying Vaginal Estrogen for Prevention of Recurrent Urinary Tract Infections) Trial

Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections

Condition
Recurrent Urinary Tract Infection
Intervention / Treatment

-

Contacts and Locations

Cranberry Township

UPMC Lemieux Sports Complex, Cranberry Township, Pennsylvania, United States, 16066

Erie

UPMC Hamot, Erie, Pennsylvania, United States, 16550

Pittsburgh

University of Pittsburgh Medical Center-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States, 15213

Pittsburgh

UPMC Passavant-McCandless, Pittsburgh, Pennsylvania, United States, 15237

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Postmenopausal (definition: No menses for 1 or more years or surgical menopause (bilateral oophorectomy). If there is a past history of hysterectomy, patient must be age 56 or older (95th percentile for age at menopause) or have laboratory evidence of menopause (ie. FSH \>30)
  • * Meets criteria for recurrent urinary tract infections (UTIs) with 2 or more UTI in 6 months or 3 or more UTI in 1 year
  • * May include patients who used vaginal estrogen previously if they have stopped use for 3 or more months prior to inclusion into study.
  • * Patients must be recommended vaginal estrogen as part of normal clinical care for prevention of recurrent UTI
  • * Current use of vaginal or oral estrogen products
  • * Inability or refusal to use vaginal estrogen
  • * Daily antibiotic use
  • * Significant vaginal stenosis (eg. due to lichen sclerosis, radiation or obliterative prolapse surgery) that would prohibit use of a vaginal applicator (ie. genital hiatus \<1cm)
  • * Inability to use vaginal applicator and without caregiver who can administer (eg. provider-managed pessary use, significant arthritis)
  • * Frequent (1x weekly or more frequent) use of bladder instillations containing an antibiotic
  • * Known hydronephrosis as a result of incomplete bladder emptying
  • * Use of intermittent or indwelling urinary catheterization
  • * Known bladder stones, mesh erosion into bladder, or foreign object in bladder
  • * Unable to consent for self
  • * Active treatment for an estrogen-dependent malignancy

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mary Ackenbom,

Stephanie W Zuo, MD, PRINCIPAL_INVESTIGATOR, University of Pittsburgh Medical Center

Study Record Dates

2025-05-30